(Q34808062)

4 August 2017

1 reference

title

Acute myeloid leukaemia: optimising treatment in elderly patients (English)

1 reference

4 August 2017

1 reference

Graham H Jackson

1

1 reference

4 August 2017

Penelope R A Taylor

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

19

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

571-581

1 reference

Age cohort subgroups in adult acute myeloid leukaemia studies--the population perspective

4 August 2017

cites work

1 reference

12 December 2020

Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly

1 reference

12 December 2020

Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study

1 reference

12 December 2020

Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia

1 reference

12 December 2020

Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome

1 reference

12 December 2020

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group

1 reference

12 December 2020

Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.

1 reference

12 December 2020

Quality and quantity of survival in acute myeloid leukaemia

1 reference

12 December 2020

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells

1 reference

12 December 2020

Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group

1 reference

12 December 2020

Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk

1 reference

12 December 2020

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B

1 reference

12 December 2020

De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group

1 reference

12 December 2020

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group

1 reference

12 December 2020

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study

1 reference

12 December 2020

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

12 December 2020

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

1 reference

12 December 2020

The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy

1 reference

12 December 2020

Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

1 reference

12 December 2020

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.

1 reference

12 December 2020

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

1 reference

12 December 2020

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

12 December 2020

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group

1 reference

12 December 2020

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

12 December 2020

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...]

1 reference

12 December 2020

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

12 December 2020

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

1 reference

12 December 2020

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

12 December 2020

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

12 December 2020

Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C.

1 reference

12 December 2020

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.

1 reference

12 December 2020

Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.

1 reference

12 December 2020

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

12 December 2020

10.2165/00002512-200219080-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1046727873

0 references

1 reference